TORONTO, March 18 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. today announced that new findings were presented showing a mortality reduction in endotoxemic patients through the combined use of Spectral’s EAA(TM) Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, and Toray Medical Company’s Toraymyxin(TM) column, a blood purification device that absorbs endotoxin from the bloodstream. The findings will be presented in a symposium entitled “Measuring and targeting endotoxin in critical illness - from theory to practice” at the 28th International Symposium on Intensive Care and Emergency Medicine. The conference takes place in Brussels, Belgium from March 18-21, 2008 and focuses on developments in research, therapy, and management of critically ill patients.
“Our unique EAA(TM) diagnostic offers critical care physicians valuable information on the diagnosis of endotoxemia. Used in combination with Toray’s therapy, EAA(TM) provides actionable data that has the potential to lead to a reduction in mortality as demonstrated by the findings presented at this important conference,” said Dr. Paul Walker, President and CEO of Spectral Diagnostics. “Toraymyxin(TM) is highly effective in removing endotoxin from the bloodstream and our EAA(TM) product has the ability to identify patients who could benefit from the therapy and monitor its results. Together, the combined diagnostic and therapeutic has the potential to provide a more effective treatment for patients with endotoxemia.”
Data compiled using Spectral’s EAA(TM) will also be featured in several posters being presented at the conference. A manuscript describing the study of the combined use of EAA(TM) and Toraymyxin(TM) is currently being written and will be submitted for publication in 2008.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral’s lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
CONTACT: Dr. Paul Walker, President & CEO, (416) 626-3233 ex. 2100; James
Smith, Investor Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com